Table 1.
Baseline patient, and tumor characteristics stratified for radiosurgery (SRS) modality
| Whole cohort No. pts (%) |
Arm-A No. pts (%) |
Arm-B No. pts (%) |
|
|---|---|---|---|
| 251 (100) | 121 (48.2) | 130 (51.8) | |
| Median age [years (range)] | 63 (37–84) | 62 (37–83) | 63 (37–84) |
| Gender | |||
| Male | 139 (55.0) | 68 (56.2) | 71 (54.6) |
| Female | 112 (45.0) | 53 (43.8) | 59 (45.4) |
| KPS | |||
| 70 | 13 (5.2) | 6 (5.0) | 7 (5.4) |
| 80 | 35 (13.9) | 19 (15.7) | 16 (12.3) |
| 90–100 | 203 (80.9) | 96 (79.3) | 107 (82.3) |
| Tumor histology | |||
| NSCLC | 143 (57.0) | 66 (54.6) | 77 (59.2) |
| Breast cancer | 39 (15.5) | 23 (19.0) | 16 (12.3) |
| Malignant melanoma | 24 (9.6) | 8 (6.6) | 16 (12.3) |
| RCC | 25 (10.0) | 13 (10.7) | 12 (9.2) |
| Other (GI/HN/HCC/GU) | 20 (8.0) | 11 (9.1) | 9 (6.9) |
| Stage at diagnosis | |||
| I–III | 118 (47.0) | 59 (48.8) | 59 (45.4) |
| IV | 133 (53.0) | 62 (51.2) | 71 (54.6) |
| Extracranial metastases | 39 (15.5) | 17 (14.1) | 22 (16.9) |
| Brain metastases | 42 (16.7) | 22 (18.2) | 20 (15.4) |
| Extracranial and brain metastases | 52 (20.7) | 23 (19.0) | 29 (22.3) |
| EC met at time of SRS | |||
| No | 88 (35.1) | 46 (38.0) | 42 (32.3) |
| Yes | 163 (64.9) | 75 (62.0) | 88 (67.7) |
| RPA class | |||
| I | 39 (15.5) | 23 (19.0) | 16 (12.3) |
| II | 212 (84.5) | 98 (81.0) | 114 (87.7) |
| Systemic therapy after SRS | |||
| No | 62 (24.7) | 35 (28.9) | 27 (20.8) |
| Yes | 189 (75.3) | 86 (71.1) | 103 (79.2) |
| Chemotherapy | 89 (35.5) | 38 (31.4) | 51 (39.2) |
| Targeted therapy | 51 (20.3) | 28 (23.1) | 23 (17.7) |
| Immune therapy | 38 (15.1) | 14 (11.6) | 24 (18.5) |
| Hormonal therapy | 11 (4.4) | 6 (5.0) | 5 (3.8) |
No., Number; pts, Patients; SRS, Radiosurgery; KPS, Karnofsky performance scale; NSCLC, Non small cell lung cancer; RCC, Renal carcinoma cancer; GI, Gastrointestinal; HN, Head and neck; HCC, Hepatocellular carcinoma; GU, Genitourinary; EC met, Extracranial metastases; RPA, Recursive partial analysis